Targeting a growth factor to improve treatment for acute myeloid leukemia.
Targeting Autocrine Hepatocyte Growth Factor (HGF) Production as a Therapeutic Modality in Acute Myeloid Leukemia (AML)
This study is looking at how a special protein called hepatocyte growth factor (HGF) affects the survival of leukemia cells in older patients with acute myeloid leukemia (AML), and it aims to see if blocking HGF with a specific treatment can help improve the effectiveness of chemotherapy and overall outcomes for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10751039 on NIH RePORTER |
What this research studies
This research focuses on acute myeloid leukemia (AML), a serious blood cancer that often has poor outcomes, especially in older patients. The study investigates the role of hepatocyte growth factor (HGF) in the survival of leukemia cells and aims to use a monoclonal antibody to inhibit HGF in combination with chemotherapy. By analyzing blood samples from patients, the researchers hope to identify biomarkers that predict treatment response and improve patient outcomes. The approach is based on previous findings that showed promising clinical responses when targeting HGF.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with acute myeloid leukemia, particularly those who have not responded well to standard treatments.
Not a fit: Patients with other types of leukemia or those who are not eligible for chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with acute myeloid leukemia, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting the HGF/c-MET axis in leukemia treatment.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Wang, Victoria — University of California, San Francisco
- Study coordinator: Wang, Victoria
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.